ARTICLE | Company News

Ligand, Eli Lilly deal

January 2, 2012 8:00 AM UTC

Ligand and Eli Lilly partnered to formulate the pharma's products with Ligand's Captisol modified beta-cyclodextrin reformulation technology. There is no limit to the number of products Lilly can select to be reformulated. Ligand, which will receive $1 million up front, said the technology optimizes the solubility and stability of drugs. Details were not disclosed. ...